1230 QT PDev
BioCentury & Getty Images

Product Development

Dec. 30 Quick Takes: Approval for Sinopharm vaccine, following report of 79% protection; plus Aprea, Axsome, Serum Institute, Pfizer-BioNTech, Moderna, Inotrem and Actinium

By Sandi Wong, Assistant Editor, And Lauren Martz, Senior Editor
Dec 31, 2020 | 3:12 AM GMT
Editor's note: Updated to reflect conditional approval for Sinopharm vaccine Updated on Jan 1, 2021 at 3:09 AM GMT

Sinopharm reveals top-line Phase III data
China’s National Medical Products Administration (NMPA) granted conditional approval late

Read the full 554 word article

How to gain access

Continue reading with a
two-week free trial.